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1. INTRODUCTION 
Prostate cancer (PCa) is the second most common cancer in men, only behind lung cancer, with an estimated 
incidence of 990,345 cases worldwide in 20201. Detection at an early stage relies essentially on prostate-
specific antigen (PSA) presence in serum and digital rectal examination (DRE), followed by a trans-rectal 
biopsy if results show it to be necessary2. Primary treatment consists mainly of radical prostatectomy and 
radiotherapy, combined with androgen deprivation therapy (ADT) in more advanced conditions of the disease. 
Although PCa has a good prognosis and ADT reports favorable results in most cases, it can progress and reach 
a stage called Castration Resistant Prostate Cancer (CRPC) and develop metastasis3. Existing treatments for 
CRPC are palliative4 and that is the reason why it is necessary to explore new strategies to address the disease. 
Regarding that issue, the development of precision medicine has become one of the main objectives in cancer 
and it seems increasingly crucial to find biomarkers that allow both to stratify patients and to propose a 
personalized treatment5. 
Previous studies have described the transcriptional coactivator PPAR gamma co-activator 1 alpha (PGC1⍺) as 
a possible biomarker for the stratification of patients with PCa6. PGC1⍺	is a transcriptional coactivator that 
acts through different transcription factors or nuclear receptors, creating interactions across various N-terminal 
LXXLL leucine-rich motifs. It belongs to the PGC1 family and it is expressed mainly in tissues with a large 
number of mitochondria or that require a great oxidative metabolism, such as heart, skeletal muscle, brown 
adipose tissue, brain and kidney7. As PGC1⍺ is considered an essential modulator of cell metabolism, its 
implication in cancer has been studied over the past years.	
Nonetheless, the role of the transcriptional coregulator PGC1⍺ in cancer is complex and it seems to be related 
to the context and tissue-specific characteristics. In the case of melanoma, the increased expression of PGC1⍺ 
is related to proliferation and survival; however, it reduces cells’ invasive abilities. Accordingly, metastatic 
cells in melanoma cancer have a reduced expression of PGC1⍺7. In breast cancer, PGC1⍺ also favors cell 
growth and proliferation and modulates the response to some treatments8. As well as in melanoma cells, in 
PCa PGC1⍺ has been observed to have anti-metastatic activity. It has also been proven its role in suppressing 
the proliferation of PCa cells, in addition to reducing anchorage-independent growth and burden tumor, 
something that did not occur in melanoma9, 6. 
As discussed above, PGC1⍺ performs its functions by interacting with different transcription factors, including 
ERR⍺. Estrogen-related receptor (ERR) is a family of ligand-activated transcription factors that have a C-
terminal ligand-binding domain (LBD) to interact with PGC1⍺, among others, and a zinc-finger DNA binding 
domain (DBD) to recognize and bind specific DNA sequences in order to carry out their functions as a 
transcription factor10. PGC1⍺/ERR⍺ transcriptional axis has been shown to be of great importance in cancer 
cells’ metabolism, although its effect is, as mentioned earlier, dependent on the type of tumor 11. In the specific 
case of PCa, PGC1⍺ operates in an ERR⍺	dependent manner, thus controlling the invasive phenotype of 
cancer, as well as the proliferation, decreasing both of them9. In PCa cell lines, PGC1⍺ has also been reported 
to reduce the cell cycle progression and to arrest cells in G1 phase6. 
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However, despite PGC1⍺’s role in the stratification of patients, it remains necessary to study its molecular 
mechanisms so that it can be targeted for personalized treatment. With that in mind, the laboratory performed 
an RNAseq of PCa cell lines with differential expression of PGC1⍺. The preliminary data revealed more than 
4,500 upregulated genes in the presence of PGC1⍺, many of them related to oxidative metabolism and 
mitochondrial functions, as mentioned. In addition, it showed more than 3,000 downregulated genes, among 
which are some genes related to cell cycle, E2F and Myc target genes, for example. 
Cell cycle (Figure 1) is regulated in several ways, one of the main ones being the 
phosphorylation/dephosphorylation of different proteins by cyclin/cyclin-dependent protein kinases (CDKs) 
complexes. These complexes act on cell cycle checkpoints and their objective is to control cell cycle 




Figure 1. Cell cycle phases diagram. Checkpoints and cyclins and CDKs involved on each 




Retinoblastoma (Rb) protein is involved at several stages of the cell cycle but more specifically in the G1-to-
S transition. This tumor suppressor is phosphorylated and dephosphorylated by diverse cyclin/CDK 
complexes; when dephosphorylated, Rb binds to the E2F transcription factor and remains bound as the cell 
enters G1 phase and it is mono-phosphorylated by cyclin D/CDK4-6 complex. Then, in late G1, Rb is multi-
phosphorylated by cyclin E/CDK2 and consequently, the Rb/E2F complex dissociates13. E2F is a family of 
transcription factors that target MCM (minichromosome maintenance protein complex) genes, CDC6 or 
cyclins D and A among others, being closely associated with cell cycle progression and the transition to the 
DNA replication phase. When E2F interacts with Rb, the latter blocks the function of the E2F transcription 
factor and cells remain arrested in G1. Therefore, Rb phosphorylation at several residues is necessary for 
dissociation to occur and for E2F to fulfil its function14. 
Cancer cells show an increased function of cyclin/CDK complexes and, in consequence, increased levels of 
Rb phosphorylation, resulting in deregulation of E2F function and uncontrolled proliferation, as mentioned 
above15. In addition, in PCa, proliferative androgen receptor (AR) signaling is known to be crucial for tumor 
development and survival16. AR is a nuclear transcription factor that affects E2F and Rb signaling in several 
ways, for example enhancing  the expression of cyclin D and the formation of cyclin D/CDK4 complexes, 
which would lead, once again, to the phosphorylation of Rb and its loss of function as a repressor of E2F17. 
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2. HYPOTHESIS AND OBJECTIVES 
We have mentioned that coactivator PGC1⍺ has been shown to play an anti-proliferative role in PCa cells. 
Likewise, one of the characteristics of cancer is its uncontrolled cell proliferation due to cell cycle deregulation. 
Taking into account that preliminary information, we hypothesize that PGC1⍺ regulates the progression of the 
cycle and the G1-to-S phase transition targeting E2F transcriptional program. To this end, we aim to analyze: 
first, the transcriptional program associated with PGC1⍺ and related to cell cycle; second, the activity of CDK4 
and associated proteins; and lastly, the correlations between PGC1⍺ and its transcriptional program in patients.  
 
3. MATERIALS AND METHODS 
3.1. Materials. 
 3.1.1. Cell lines. 
Human prostate carcinoma cell line PC3, which had been previously transduced with a modified TRIPZ 
doxycycline-inducible lentiviral construct containing mouse PGC1⍺ sequence (PC3 TRIPZ-HA-PGC1α), was 
used to perform all of the experiments.  
 3.1.2. Cell culture conditions. 
Cell lines were maintained using Dulbecco’s Modified Eagle’s Medium (DMEM) with glucose, L-glutamine, 
phenol red and no sodium pyruvate. DMEM was supplemented with 10% (v/v) inactivated Fetal Bovine Serum 
(FBS) and 1% (v/v) Penicillin-Streptomycin (complete medium).  
Manipulation of cells was performed under sterile conditions in laminar flow cabinets. Cells were cultured in 
100 mm dishes and incubated at 37 ºC in 21% O2 and 5% CO2. For preservation, cells were frozen in Dimethyl 
Sulfoxide (DMSO) 10% (v/v) in FBS solution at -80 ºC after centrifugation (1200 rpm, 4 minutes, room 
temperature). On another note, fresh complete medium was added to cryovials for defrosting. As DMSO is 
toxic for cells and in order to prevent cells’ death, the medium had to be changed the following day. 
Routine cell passages were made every 3-4 days. For detaching, cells were washed with Dulbecco’s Phosphate 
Buffered Saline (DPBS) (1X) and incubated for 3 minutes at 37 ºC with 0.25% Trypsin-EDTA (1X) (Gibco) 
1:4 DPBS dilution. DMEM was added to inactivate trypsin and resuspended cells were then diluted in complete 
media depending on initial confluence and seeded in a new plate.  
To count cells, after the resuspension step, they were diluted 1:2 in 0.4% Trypan Blue Dye and counted in a 
Neubauer chamber using optical microscopy. Only death cells are blue-stained, as Trypan Blue Dye only enters 
the cytoplasm of cells whose membrane has been disrupted. That made possible to count viable (non-stained) 
cells.  
0.5 µg/mL of doxycycline hyclate (Dox) (Sigma #D9891) were used to induce PGC1⍺ expression in PC3 
TRIPZ-HA-PGC1α cells.  
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3.5. Data mining. 
The laboratory had previously performed an RNAseq with PGC1α expressing cells (Dox) and non-expressing 
cells (No Dox). A functional enrichment of the PGC1α expressing cells’ upregulated and downregulated genes 
was performed using Cancertool18, focusing on Biocarta and Pathway enrichment types. In addition, Gene Set 
Enrichment Analysis (GSEA) was also used to carry out a complementary enrichment19. Both analyses were 
performed to determine the functions that were enriched in PGC1⍺ expressing condition (Dox). A group of 
genes that are included in the enriched cell function was selected for subsequent experiments. 
Once candidate genes were chosen, Cancertool’s “Correlations” feature was used to study correlation among 
that set of genes expression and PGC1⍺ on PCa patients. 
3.3. Cellular analysis. Cell growth curve.  
Cell growth at differential PGC1⍺ expression conditions was analyzed. To induce PGC1⍺, cell lines were pre-
treated with dox. After 3 days, both doxycycline-treated and non-treated cells were resuspended, counted and 
seeded (10,000 cells/well) in technical triplicates with complete DMEM media in three 12-well-plates, 
corresponding to day 0, day 3 and day 6 of incubation. 
Cells were fixed at day 0, day 3 and day 6 with formalin 10% after washing off non-adherent death cells with 
DPBS. Plates were stored at 4 ºC until quantification. Crystal violet 0.1% (in 20% methanol) was used to stain 
attached cells, as it binds to DNA and proteins.  
After shaking for 60 minutes, crystal violet was washed with distilled water, air-dried and resolubilized using 
10% acetic acid for 1 hour. Resolubilized crystal violet was then transferred to a 96-well-plate to measure the 
absorbance (570 nm) using PowerWave XS Microplate Spectrophotometer (BioTek). The OD measured was 
directly proportional to the attached cell number and this allows to measure cell growth20. 
3.4. Molecular analysis. 
 3.4.1. Gene expression analysis. 
As in growth analysis, doxycycline was used to pre-induce cells for three days before they were seeded (75,000 
cells/well) in a 6-well-plate in a final volume of 2 mL in triplicate. Cells were incubated in DMEM for 3 days, 
then plates were frozen in liquid N2 and stored at -80 ºC after washing them with DPBS (1X). For time course 
experiment a different number of cells were seeded (400,000 cells/well) and were induced with doxycycline 
2, 4, 6 or 8 hours before recollecting them.  
RNA was extracted using NucleoSpin RNA isolation kit from Macherey-Nagel (ref: 740955.240C) following 
manufacture instructions and concentration was measured with a BioDrop spectrophotometer (Biochrom). To 
assess RNA purity, 260/280 nm and 260/230 nm ratios were considered; appropiate values are ~2.0 and ~2.0-
2.2, respectively.  
For cDNA synthesis, 1 µg of RNA was mixed with 2 µL of Thermo Scientific Maxima H Minus cDNA 
synthesis Master Mix (5X) and diluted up to 8 µL with RNase-free water and. cDNA synthesis was performed 
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in a thermocycler at 25 ºC for 10 minutes, at 50 ºC for 15 minutes and lastly, at 85 ºC for 5 minutes. The 
resulting cDNA product was diluted 1:9 in RNase-free water and stored.  
For gene expression characterization, quantitative real-time PCR (qPCR) was performed using the Applied 
Biosystems QuantStudio 5 Real-Time PCR System (384-Well Block). CDC25A, CDK4, MCM7, E2F8 and 
MCM2 genes were analyzed using TaqMan technology, while MCM10, ORC1, WEE1, CDC7 and CDC45 
genes were studied using SYBR Green technology. TaqMan assay relies on the use of gene-specific probes, 
besides gene-specific primers, consisting of a 3’ quencher and a 5’ reporter that release fluorescence when the 
gene is amplified. SYBR Green, on the other side, is a DNA intercalating agent that binds double strand DNA 
and emits more fluorescence than in solution. Therefore, as DNA is amplified using gene-specific primers, 
fluorescence emission increases, enabling us to measure the DNA product21. 
For TaqMan amplified genes, 3 µL of TaqMan Universal Master Mix II, with UNG 2X (Applied Biosystems), 
forward and reverse primers (Supplementary Table 1) at a final concentration of 200 nM and gene-specific 
probes at a concentration of 100 nM were mixed and loaded to a 384-well-plate, before loading 3 µL of 
previously diluted cDNA (final volume = 6 µL). For SYBR Green, 3 µL of FastStart Universal SYBR Green 
Master (Roche) were mixed with forward and reverse primers (Supplementary Table 1) at a final 
concentration of 200 nM and loaded to the plate, so that 3 µL of cDNA could be added.  
The following amplification program was used for TaqMan: 2 minutes at 50 ºC, 10 minutes at 95 ºC and, 
finally, 40 cycles of 15 seconds at 95 ºC for denaturalization and 1 minute at 60 ºC for annealing and elongation. 
For SYBR Green reaction the program was: 50 ºC for 2 minutes and 95 ºC for 10 minutes before 40 cycles of 
95 ºC for 15 seconds and 60 ºC for 1 minute, to end with 95 ºC for 15 seconds, 60 ºC for 1 minute and 95 ºC 
for other 15 minutes.  
In both TaqMan and SYBR Green reactions, data obtained from amplified genes was normalized using a 
housekeeping gene, GAPDH in our case.  
 3.4.2. Protein expression analysis. 
For protein analysis, the same experimental setup as for RNA extraction was used (75,000 cells/well were 
seeded). 
The plates were thawed in ice and cells’ lysis was accomplished using 75 µL of RIPA lysis buffer (see 
Supplementary Table 2) per well. Cells were transferred to Eppendorf tubes and maintained on ice for 30 
minutes, while vortexed every 4 minutes. After centrifugation (10 minutes, 14,000 g, 4 ºC), supernatant was 
collected and transferred to new Eppendorf tubes. For protein quantification, PierceTM BCA Protein Assay Kit 
(Thermo Fisher Scientific, ref: 23225) was used. First, we prepared a calibration curve with increasing 
concentrations of Bovine Serum Albumin (BSA) from 0.5 to 8 mg/mL. Samples were prepared by mixing 1 
µL of the previously extracted protein with 9 µL of mili-Q water. BSA and samples were then loaded in 
duplicate to a 96-well-plate, 200 µL of BCA reagent was added to every well and the plate was incubated for 
30 minutes at 37 ºC afterwards. Absorbance was measured at 562 nm using PowerWave XS Microplate 
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Spectrophotometer (BioTek). Protein concentration was equaled in all samples by adding mili-Q water and 
Laemmli Loading Buffer 5X (see Supplementary Table 3).  
In order to analyze proteins of interest, we performed a Western Blot. For that, samples were heated at 95 ºC 
for 5 minutes and then subjected to SDS-PAGE, in which proteins were separated depending on their size. 
Both precast gels (CriterionTM XT Precast gels, 4-12% acrylamide, 12+2 well, BioRad) and homemade gels 
(resolving 7.5% and stacking 5% acrylamide, see Supplementary Table 4) were used. For each experiment 
and condition (Dox and No Dox) 15 µg (handmade gels) and 10 µg of protein (precast gels) were loaded in 
duplicate and Nippon MWP02 (DDBiolab) was used as a weight marker.  
Electrophoresis was conducted in 1X Tris/Glycine/SDS running buffer at 90V for 15 minutes first and 150V 
for 1 hour afterwards in the case of homemade gels and in MOPS buffer at 180V for 90 minutes in the case of 
precast gels. In both homemade and precast gels, proteins were transferred to nitrocellulose membranes in 
transfer buffer 1X (10% transfer buffer 10X, composition in Supplementary Table 5, 20% ethanol, 70% mili-
Q water) and the transference was carried out at 100V for 1 hour and 80V for 90 minutes, respectively. To 
assure that proteins were successfully transferred, membranes were stained with Ponceau S dye (0.1% (x/v) 
Ponceau S in 1% (v/v) acetic acid). 
Before incubation with antibodies, membranes were blocked using 5% non-fat milk in Tris-Buffered Saline 
Solution with 0,01% Tween-20 (TBST) and washed also with TBST 1x. TBST with 0.002% sodium azide was 
used to prepare primary antibodies (the antibodies used are listed in Supplementary Table 6) at 1:1000 
dilution, excluding β-actin, which was prepared at 1:2000. Membranes were incubated with primary antibodies 
overnight at 4 ºC. For secondary antibody incubation, membranes were washed with TBST 1x and incubated 
for 1 hour at room temperature. Secondary antibodies were anti-rabbit (30111-035-144, Vitro s.a.) and anti-
mouse (S30315-035-0454, Vitro s.a.) and were diluted 1:4000 in %5 non-fat milk in TBST. For membrane 
processing, ClarityTM Western ECL Substrate (Bio-Rad) and ChemiDoc Imaging System (Bio-Rad) were used.  
GraphPad Prism 8 software was used for the statistical analysis of fold change relative to No Dox condition. 
One-sample t-test was performed, with a hypothetical value of 1 and confidence level of %95 (⍺=0.05).  
3.5. Statistical analysis. 
GraphPad Prism 8 software was used for the statistical analysis of fold change relative to No Dox condition. 
One-sample t-test was performed, with a hypothetical value of 1 and confidence level of %95 (⍺=0.05). All 
experiments were repeated three times to ensure adequate statistical power. 
 
4. RESULTS 
4.1. Cell growth at differential PGC1⍺	expression. 
Prior studies had shown that PGC1⍺	suppresses PCa growth. In order to confirm that our in vitro experimental 
system was performing well, proliferation under PGC1⍺expressing (Dox) and non-expressing (No Dox) 
conditions was examined. As predicted, PGC1⍺	expressing cells showed a significantly decreased in cell 
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proliferation compared to non-expressing ones both at day 3 and day 6 (Figure 2). Taking into account 
previous laboratory experiments, the possibility that doxycycline treatment could affect the result was 
excluded6.  
 
Figure 2. Cell growth at differential PGC1⍺	expression of PC3 TRIPZ-HA-PGC1α cells. Cells were 
incubated for 3 and 6 days (N=3 independent experiments). Growth of Dox induced cells is 
represented relatively to No Dox condition (dotted line, value=1.0). D3=Day 3; D6=Day 6. Asterisk 
indicate statistical difference between 1.0 (No Dox) and Dox condition: ***, p < 0,001; **, p < 0,01; 
*, p < 0.05. Quantifications are presented as mean with SEM. 
 
4.2. Data mining.  
As mentioned, the laboratory had performed an RNAseq with PGC1⍺	expressing and non-expressing cells and 
the results showed more than 4,500 upregulated and more than 3,000 downregulated genes in the presence of 
PGC1⍺.	We performed a functional enrichment analysis of that list of genes using Cancertool, focusing on 
those genes that appear downregulated in Dox condition, therefore being upregulated in No Dox condition. 
Different enrichment analysis were carried out by Cancertool, but we gave particular attention to Biocarta and 
Pathway (Figure 3).  
On one side, Biocarta results show a significant downregulation of genes related to G2 cell cycle phase, in 
addition to MCM genes, which are as well related to cell cycle and mitosis. Furthermore, Pathway results 
reveal that cell cycle is the feature that is downregulated with the highest significance. Mitosis and mitosis 
related processes also appear to be downregulated in Dox condition, according to the information obtained 
from the enrichment. 
 
 
Figure 3. Functional enrichment analysis results 
provided by Cancertool. The ten terms with the 
highest significance according to adjusted p-value 
are shown. A) Biocarta enrichment and B) 
Pathway enrichment. The X-axis indicates the -
log10 of the adjusted p-value and the Y-axis 
contains information about the category, the ratio 
(count/size, size being the number of genes 
assigned to the category and count the gene count 
from the provide list that correspond to the 
category) and the adjusted p-value (Padj)18. 
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Next, we performed an additional enrichment using GSEA. We found that gene sets that are enriched in PC3 
cells without PGC1⍺	expression (No Dox condition), that is, aggressive cells, are mainly E2F targets and 
Myc targets (Figure 4). Myc is a target gene of PGC1⍺	(referencia) and E2F targets are associated with cell 
cycle and cell cycle progression. 
Figure 4. Functional enrichment analysis results for E2F and Myc targets provided by GSEA. The enrichment score (ES) on the X-
axis reflects the degree to which a gene set is overrepresented at the top or bottom of a ranked list of genes. The negative ES indicates 
gene set enrichment at the bottom of the ranked list at No Dox condition (blue region, Dox condition being red region)19. NES 
(Normalized Enrichment Score) values from left to right are -3.62, -2.85 and -2.58. FDR (False Discovery Rate) q-value is the estimated 
probability that a gene set with a given NES represents a false positive finding. The values from left to right are 0.000, 0.000 and 0.000. 
 
Taking into account the information obtained from functional enrichment and bibliographic research, 11 genes 
which appear downregulated on PGC1⍺	expressing cells (Dox condition) were selected for further analyses, 
all of them being related to cell cycle: CDC6, CDC25A, MCM10, MCM2, MCM7, CDK4, ORC1, E2F8, 
WEE1, CDC7 and CDC45. Using Cancertool, we studied gene expression correlation between PGC1⍺	and all 
the candidate genes in PCa patient datasets (Figure 5).  
 
Figure 5. Heatmat provided by Cancertool for correlation 
between PGC1⍺	 and the genes on the right in multiple 
datasets. Red color shade indicates a direct correlation 
(correlation coefficient toward 1) and blue color shade 
indicates an inverse correlation (correlation coefficient 
toward -1). Correlations on concrete datasets are indicated 
with asterisks following the criteria: p ≤ 0.05 and 
Spearman correlation coefficient greater than 0.2 or lower 
than -0.2 for direct or inverse correlations, respectively. On 
the left side, the coherence among data sets is shown for 
each pair of genes (significant correlation in more than 
50% of datasets)18. 
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While none of the candidate genes shows significant correlation in more than 50% of datasets (consistency), 
CDK4 and MCM7 show significance in Taylor and TCGA (The Cancer Genome Atlas) cohorts, besides 
exhibiting solid correlation also in Glinsky and Grasso datasets, respectively. The number of PCa patients in 
those datasets is larger and the clinical data is better characterized18. 
 
4.3. Cell cycle related PGC1⍺ transcriptional program. 
Considering the information obtained from data mining and functional enrichment analyses, we next 
performed a gene expression profiling of PGC1⍺	expressing (Dox) and non-expressing (No Dox) PC3 cell 
lines. In order to validate that candidate genes were downregulated in PGC1⍺	expressing cells, as it was 
previously observed in the RNAseq analysis, various qPCR were carried out. As we had predicted, all of the 
genes had a reduced expression in Dox induced condition (Figure 6). CDC6 gene expression could not be 
analyzed since TaqMan probe and/or primers did not work as expected and the gene could not be amplified 
nor measured. 
Figure 6. mRNA Expression of candidate genes (left panel) and PGC1a (right panel) in PC3 TRIPZ-HA-PGC1α cells incubated for 
3+3 days. (N=3 independent experiments). Expression in Dox induced cells is represented relatively to No Dox condition (dotted line, 
value=1.0). Asterisk indicate statistical difference between 1.0 (No Dox) and Dox condition: ***, p < 0,001; **, p < 0,01; *, p < 0.05. 
Quantifications are presented as mean with SEM.  
 
4.4. Protein expression. Rb phosphorylation under PGC1⍺	expression. 
As data mining pointed that CDK4 was a gene of interest, was validated by qPCR and knowing from literature 
that it is involved in Rb phosphorylation and cell cycle progression, we considered analyzing protein 
expression and Rb phosphorylation in PC3 cell line. PGC1⍺-expressing (Dox) and non-expressing (No Dox) 
cells’ expression of CDK4, cyclin D1 and total Rb, as well as phospho-Rb were compared and the results are 
displayed in Figure 7.  
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Figure 7. Effect of PGC1⍺ expression in CDK4, cyclin D1 and Rb protein expression, in addition to Rb phosphorylation in Ser780 
residue. A) Representative Western Blot results out of three experiments. Experiments were performed in PC3 TRIPZ-HA-PGC1α 
cells incubated for 3+3 days. (N=3 independent experiments). B) Quantification of the protein expression level. Expression in Dox 
induced cells is represented relatively to No Dox condition (dotted line, value=1.0). Asterisk indicate statistical difference between 1.0 
(No Dox) and Dox condition: ***, p < 0,001; **, p < 0,01; *, p < 0.05. Quantifications are presented as mean with SEM.  
 
CDK4 shows a significant decrease of expression in PGC1⍺ presence. Although cyclin D1, with which CDK4 
works on Rb mono-phosphorylation, does not reach confidence level, it also shows a reduction compared to 
No Dox condition. In addition, phospho-Rb/total-Rb ratio appears decreased in PGC1⍺ expressing cells, 
therefore showing a decreased phosphorylation of Rb protein. As can be noted in the left panel of Figure 7, 
besides the reduction in Rb phosphorylation, total-Rb protein expression also reveals a reduction in Dox 
condition, that is to say, under PGC1⍺	expression. The results corroborate that PGC1⍺	impacts not only on 
both CDK4 gene and protein expression, but also on Rb phosphorylation and total Rb, molecular events that 
could affect cell cycle progression. 
 
4.5. Time course. 
To further characterize the dynamics of transcriptional	regulation of some of the selected genes(MCM10, 
MCM7 and CDK4) by PGC1⍺, a short doxycycline time course was carried out. Given the notion that cell 
cycle related genes are generally regulated by the oncogene Myc and that our lab has previously described that 
PGC1⍺	transcriptionally	represses	the	Myc	in	a	time	dependent	manner,	we	wonder	if	the	changes	in	
our	 candidate	 genes	 were downstream of Myc canonical repression triggered by PGC1⍺.	 	 The gene 
expression of the selected genes was monitor upon PGC1⍺	induction at 2, 4, 6 and 8 hours of treatment with 
doxycyclinep. Results show a significant reduction of the expression of MCM10 at 8 hours, although all of the 
genes exhibit a tendency to reduce their expression after the first 6 hours (Figure 8). Considering those results, 
it would be useful to determine additional time points in order to monitor the beginning of the decrease in the 
expression. It would also be necessary to perform some complementary experiments to ensure that Myc 
mediates MCM10, CDK4 and MCM7 expression. 
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Figure 8. Gene expression analysis of CDK4, 
MCM7 and MCM10 at 2, 4, 6 and 8 hours of 
doxycucline induction and PGC1⍺	 expression 
(N=3 independent experiments). Expression in 
Dox induced cells is represented relatively to No 
Dox condition (dotted line, value=1.0). Asterisk 
indicate statistical difference between 1.0 (No 
Dox) and Dox condition (blue for MCM10 and 
pink for CDK4): ***, p < 0,001; **, p < 0,01; *, 




PGC1⍺,	through ERR⍺,	has been demonstrated to reduce cell proliferation in PCa, besides preventing tumor 
dissemination and metastasis6,9. We confirmed that proliferative reduction of cancer cells elicited by PGC1a 
was also happening in PC3TRIPZ-HA-PGC1α cell line we were using for the subsequent experiments, as 
expected from previous studies.  
As mentioned, the laboratory had previously performed an RNAseq, obtaining more than 7000 genes either 
upregulated or downregulated in PGC1⍺ presence. Functional enrichments of RNAseq data revealed that cell 
cycle is one of the main pathways downregulated in PGC1⍺ expressing cells, thus being enriched in non-
expressing aggressive cells. Cancer is characterized by increased and uncontrolled cell proliferation, partly due 
to a signaling cascade that affects G1-to-S and G2-to-M transitions12; therefore, the results of RNAseq data 
enrichments are consistent and coherent with published information and what is described about cancer and 
cancer cells’ behavior. 
Analyzing those cell cycle-related genes, which appear downregulated in PGC1⍺	expressing cells, is of great 
relevance because it means that they appear upregulated in cells that do not express PGC1⍺ and, therefore, 
exhibit a more aggressive phenotype. That is, it would serve to identify possible therapeutic targets associated 
with PGC1⍺	expression. Taking into account the literature and the information of the RNAseq and pertinent 
enrichments, we studied the transcriptional program associated with the cell cycle in PCa PC3 cell line, both 
in PGC1⍺ expressing and non-expressing conditions. All of the candidate genes present a strong relation with 
different cell cycle processes and showed reduced expression in the case of induced cells, as predicted since it 
was described that PGC1⍺	arrested cells in G1 phase6. To assure that PGC1⍺ plays a role in cell cycle by 
conditioning the transcription of associated genes it would be convenient to make a rescue experiment of those 
genes in PGC1⍺-expressing cells and observe if proliferation is reduced and cells remain arrested in G1 phase. 
As in the functional enrichment performed by GSEA, we observed that E2F and Myc target genes were 
enriched under PGC1⍺ expression, we raised the possibility that Myc was mediating the effect of PGC1⍺ in 
  12 
the cell cycle. With that in mind, a short time course of the expression of three of the candidate genes was 
carried out. Even though results showed a significant decrease only in the case of MCM10, we can appreciate 
that the genes exhibit a reduction at 6 and 8 hours. Considering that previous studies have shown a significant 
repression of Myc expression within the first 2 hours after induction of PGC1⍺	 expression9, it could be 
suggested that Myc mediated the expression of cell cycle-related genes. Those results would be in line with 
the knowledge of that Myc affects CDK4, among others, contributing to cell cycle deregulation in cancer 
cells22,23. In order to verify that hypothesis in our cells, it would be interesting to study the expression of the 
time course genes in Myc knock out cells (shMyc cells) or, what is more, to make a rescue experiment of Myc 
in the PC3 TRIPZ-HA-PGC1α cells after the induction of PGC1⍺.	
Once we had confirmed that the inducible PGC1⍺ expression system was working, as we could see in the 
growth curve, we focused on studying CDK4 and the Rb phosphorylation/dephosphorylation axis, since CDK4 
appear in the RNAseq and its kinase activity is of great importance in the alteration of the cell cycle in cancer24. 
As mentioned, CDK4 expression is decreased in both the RNAseq and the qPCR. We wanted to check if, 
besides the gene expression, CDK4 activity was also compromised in PGC1⍺ expressing cells. Besides results 
showing that CDK4 protein expression is reduced, the ratio of phosphorylated Rb compared to the total Rb is 
decreased in cells expressing PGC1⍺,	hence	being	 increased	 in	aggressive	PGC1⍺-non-expressing cells. 
This is consistent with the previous studies describing a deregulation of CDK4 activity in a wide variety of 
tumors, in which CDK4 exhibits a higher activity and therefore, Rb phosphorylation-rate is elevated25. As 
mentioned, Rb phosphorylation is necessary for cell cycle progression, since that way Rb dissociates from 
E2F, leading to cell cycle-related genes transcription14. 
However, even though Rb does not appear decreased under PGC1⍺	in the RNAseq data, the total amount of 
Rb does appear reduced in the protein analysis, in addition to the reduction of the phosphorylation. The same 
happens in the case of cyclin D1, so we can speculate that in both cases the decrease occur at protein translation 
level, protein stability or both. In any case, the results are consistent with the prediction: in PGC1⍺	expressing 
cells, important cell cycle related genes are reduced, as Rb phosphorylation is crucial for G1-to-S phase 
transition26. Moreover, correlations carried out by Cancertool showed an inverse relationship between PGC1⍺	
and CDK4 in three of the seven datasets, as we could observe in the provided heatmap.  
Targeting the Rb phosphorylation process mediated by cyclin D/CDK4-6 complex may be a promising 
therapeutic strategy for treating PCa, once PGC1⍺	expression in the patient was monitored. This could lead to 
the use of PGC1⍺	as a biomarker for personalized medicine, besides its function in stratifying patients with 
low and high expression, as previously proposed 6. In breast cancer, cyclin-dependent kinases are already being 
the target of several commercialized drugs: palbociclib, ribociclib and abemaciclib. All three are CDK4/6 
inhibitors and have been shown to be highly effective in treating different subtypes of breast cancer, in 
combination with endocrine therapy27. 
Nonetheless, in PCa, results are quite disappointing so far. For example, flavoripidol, a CDK inhibitor that had 
previously shown clinical efficacy in xenografts, did not achieve the expectations in a phase II trial of 
metastatic hormone-refractory PCa28. A similar situation was described with palbociclib in the treatment of 
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Rb-expressing metastatic hormone-sensitive PCa. Palbociclib had good preclinical results but did not 
demonstrate its efficacy in a phase II trial29. Focusing on CRPC, there are currently some clinical trials to 
demonstrate the efficacy of different CDK4/6 inhibitors (NCT02494921 o NCT02905318), including the 
already mentioned palbociclib, in the treatment of CRPC30. However, it should be taken into account that 
metastatic castration-resistant prostate cancers had shown a high heterogeneity of Rb expression since, among 
multiple options, loss of Rb both at genomics and protein level may occur, due to Rb deletions, among others31. 
In those cases, targeting CDK4/6, which would lead to reduced Rb phosphorylation, may not have the expected 
results, as those patients would not have experienced hyperphosphorylation of Rb. Moreover, PGC1⍺ 
expression should be taking into account when it comes to consider clinical trials’ results. Knowing that  
PGC1⍺ decreases Rb phosphorylation, as demonstrated in the Western Blot analysis, those patients with high 
PGC1⍺ expression may not respond to the inhibition of CDK4 for the reason that they already had low 
phospho-Rb. Meanwhile, patients with low PGC1⍺ expression might show better results as their Rb 
phosphorylation is increased, compared to those whose PGC1⍺ level is much higher.  
Considering this heterogeneity, in breast cancer loss of Rb has been proposed as a biomarker to anticipate the 
results of the treatment against CDK4/632. It would be an option to use it in the same way with PCa if studies 
prove it to be effective..   
 
6. CONCLUSION.  
To summarize, our results suggest that the effect PGC1⍺/ERR⍺	axis has on cell cycle progression in PCa is 
mediated by Rb/E2F axis and cyclin D/CDK4-6 phosphorylation of Rb. That could lead to a better knowledge 
of PGC1⍺’s molecular mechanisms and could point to CDK4 as a potential target for personalized therapy in 
prostate cancer, taking into account the role of PGC1⍺ in patients’ stratification. 
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SUPPLEMENTARY DATA 
 
Supplementary Table 1. Information about the primer sequences used for TaqMan and SYBR Green amplification. 
Gene Species Forward primer (5’ - 3’) Reverse primer (5’ - 3’) 
CDC25A Human CGTCATGAGAACTACAAACCTTGA  TCTGGTCTCTTCAACACTGACC 
CDK4 Human GTGCAGTCGGTGGTACCTG  AGGCAGAGATTCGCTTGTGT 
MCM7 Human GATCCTGGTGTGGCCAAG  CCCGGCCTGTTGTGTACT 
E2F8 Human AATGACATCTGCCTTGACGA  GTAAATGCGTCGACGTTCAA 
MCM2 Human CGAAACCTGGTTGTTGCTG GGTGAAGGATTCCGATGATTC 
MCM10 Human CCCAACCCCTACAGACGATT TTCGGCCGGTCATTTTCTTG 
ORC1 Human AGAGATCTTCAGTGGTGCCA GCTGCTGCCTAATCCGATTC 
WEE1 Human TCGATATTTCTCTGCGTGGG GGCCAACTTGCAAAAGGAGA 
CDC7 Human TGAACTTCAGTGCCTAACAGT GACTCATGCTCCAGATATGGC 
CDC45 Human CAGGGATGAAGAGGAGGATGA GGTTTGCTCCACTATCTCCTC 
 
Supplementary Table 2. RIPA lysis buffer (Roche) composition. 
RIPA lysis buffer 
TrisHCl pH 7.5, 50 mM 1% Sodium deoxycholate 
NaCl, 150 mM Sodium fluoride, 1 mM 
EDTA, 1mM Sodium orthovanadate, 1 mM 
0.1% SDS Betaglycerophosphate, 1mM 
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Supplementary Table 3. Laemmli protein loading buffer composition. 
Laemmli loading buffer 5X 
10% SDS 1% β-mercaptoethanol 
Tris pH 6.8, 50 mM DTT, 10 mM 
10% H2O 0.2 mg/mL Bromophenol blue 
50% Glycerol  
 
Supplementary Table 4. Homemade acrylamide gels recipe. 
 Resolving gel 7.5% acrylamide  Stacking gel 5% acrylamide  
30% Acrylamide 7.5% 5% 
Tris (1.5 M, pH 8.8) 25% 25% 
10% SDS 1% 1% 
10% APS 1% 1% 
TEMED 0.04% 0.04% 
Milli-Q water Up to final volume Up to final volume 
 
Supplementary Table 5. Western Blot transfer buffer composition. 
Transfer buffer 10X 
Glycine, 200 mM Tris, 25 mM 
 
 
Supplementary Table 6. Information about the antibodies used for protein detection. 
Protein Isotype Reference Commercial house 
Rb Mouse IgG 9309 Cell Signaling Technology 
CDK4 Rabbit IgG 12790 Cell Signaling Technology 
Phospho-Rb Mouse IgG 9307 Cell Signaling Technology 
Β-actin Mouse IgG 3700 Cell Signaling Technology 
Cyclin D1 Mouse IgG SC-8396 HRP Santa Cruz Biotechnology 
⍺-tubulin Mouse IgG T9026 Sigma-Aldrich 
 
